Epithelium-dependent profibrotic milieu in the pathogenesis of idiopathic pulmonary fibrosis: current status and future directions

被引:22
|
作者
Xu, Xuefeng [1 ]
Dai, Huaping [2 ]
Wang, Chen [1 ,2 ]
机构
[1] Beijing Hosp, Natl Clin Res Ctr Resp Med, Beijing 100730, Peoples R China
[2] Capital Med Univ, Beijing Inst Resp Med, Beijing Chao Yang Hosp, Dept Resp & Crit Care Med,Beijing Key Lab Resp &, Beijing, Peoples R China
来源
CLINICAL RESPIRATORY JOURNAL | 2016年 / 10卷 / 02期
基金
北京市自然科学基金; 中国国家自然科学基金;
关键词
epithelial-mesenchymal interaction; idiopathic pulmonary fibrosis; inflammation; pathogenesis; wound healing; GROWTH-FACTOR-BETA; LUNG FIBROSIS; CELLS; FIBROBLASTS; MECHANISMS; EXPRESSION; APOPTOSIS; MODELS; INJURY; MYOFIBROBLAST;
D O I
10.1111/crj.12190
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background and AimIdiopathic pulmonary fibrosis (IPF) is characterized by hyperplasia of type II alveolar epithelial cells, aggregation of activated (myo)fibroblasts and excessive deposition of extracellular matrix, which will ultimately lead to lung architecture destruction with no proven effective therapies. Despite a significant increase in our understanding on the etiology and pathogenesis of IPF, the real triggers that initiate epithelial cell injury and promote fibrosis evolution are still elusive. We wanted to discuss the evolution of hypothesis on IPF pathogenesis and to suggest some new directions which need to be further elucidated. MethodsWe have done a literature search in PubMed database by using the term idiopathic pulmonary fibrosis' AND (pathogenesis OR inflammation OR wound healing OR apoptosis OR extracellular matrix OR animal model). ResultsInflammatory hypothesis had been the dominant idea for several decades which suggests that chronic inflammation drives the onset and advance of the fibrotic process. However, it is seriously challenged nowadays because lung tissues from IPF patients exhibit little inflammatory lesions. Also, anti-inflammation therapy failed to exert a beneficial effect to IPF patients. Furthermore, experimental lung fibrosis can be realized independent of inflammation. Today, modern paradigm suggests that IPF is mainly driven by the profibtic milieu formed by epithelial injury/ disability and dysregulated epithelial mesenchymal interaction. ConclusionsEpithelium-dependent profibrotic milieu formation and mesenchymal activation is the current view on the pathogenesis of IPF. New evidence from more analogous animal models may emerge and shift our thinking to a new and more faithful concept in the future.
引用
收藏
页码:133 / 141
页数:9
相关论文
共 50 条
  • [1] Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis
    Loomis-King, Hillary
    Flaherty, Kevin R.
    Moore, Bethany B.
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2013, 13 (03) : 377 - 385
  • [2] Idiopathic pulmonary fibrosis: current and future directions
    Soo, E.
    Adamali, H.
    Edey, A. J.
    [J]. CLINICAL RADIOLOGY, 2017, 72 (05) : 343 - 355
  • [3] Idiopathic pulmonary fibrosis: current understanding of the pathogenesis and the status of treatment
    Khalil, N
    O'Connor, R
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2004, 171 (02) : 153 - 160
  • [4] Future Directions in Idiopathic Pulmonary Fibrosis Research
    Blackwell, Timothy S.
    Tager, Andrew M.
    Borok, Zea
    Moore, Bethany B.
    Schwartz, David A.
    Anstrom, Kevin J.
    Bar-Joseph, Ziv
    Bitterman, Peter
    Blackburn, Michael R.
    Bradford, William
    Brown, Kevin K.
    Chapman, Harold A.
    Collard, Harold R.
    Cosgrove, Gregory P.
    Deterding, Robin
    Doyle, Ramona
    Flaherty, Kevin R.
    Garcia, Christine Kim
    Hagood, James S.
    Henke, Craig A.
    Herzog, Erica
    Hogaboam, Cory M.
    Horowitz, Jeffrey C.
    King, Talmadge E., Jr.
    Loyd, James E.
    Lawson, William E.
    Marsh, Clay B.
    Noble, Paul W.
    Noth, Imre
    Sheppard, Dean
    Olsson, Julie
    Ortiz, Luis A.
    O'Riordan, Thomas G.
    Oury, Tim D.
    Raghu, Ganesh
    Roman, Jesse
    Sime, Patricia J.
    Sisson, Thomas H.
    Tschumperlin, Daniel
    Violette, Shelia M.
    Weaver, Timothy E.
    Wells, Rebecca G.
    White, Eric S.
    Kaminski, Naftali
    Martinez, Fernando J.
    Wynn, Thomas A.
    Thannickal, Victor J.
    Eu, Jerry P.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189 (02) : 214 - 222
  • [5] Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions
    Ferrara, Giovanni
    Luppi, Fabrizio
    Birring, Surinder S.
    Cerri, Stefania
    Caminati, Antonella
    Skold, Magnus
    Kreuter, Michael
    [J]. EUROPEAN RESPIRATORY REVIEW, 2018, 27 (147):
  • [6] Current and Future Therapies for Idiopathic Pulmonary Fibrosis
    Spagnolo P.
    Bonella F.
    Vasakova M.
    Kreuter M.
    Maher T.M.
    [J]. Pulmonary Therapy, 2015, 1 (1) : 1 - 18
  • [7] Current and Future Idiopathic Pulmonary Fibrosis Therapy
    Richeldi, Luca
    Baldi, Fabiana
    Pasciuto, Giuliana
    Macagno, Francesco
    Panico, Loredana
    [J]. AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2019, 357 (05): : 370 - 373
  • [8] Idiopathic pulmonary fibrosis: Current and future treatment
    Glass, Daniel S.
    Grossfeld, David
    Renna, Heather A.
    Agarwala, Priya
    Spiegler, Peter
    DeLeon, Joshua
    Reiss, Allison B.
    [J]. CLINICAL RESPIRATORY JOURNAL, 2022, 16 (02): : 84 - 96
  • [9] Current and future treatment for idiopathic pulmonary fibrosis
    Choi, Won-Il
    [J]. JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2021, 64 (04): : 256 - 263
  • [10] PATHOGENESIS OF IDIOPATHIC MYELOFIBROSIS - PRESENT STATUS AND FUTURE-DIRECTIONS
    REILLY, JT
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1994, 88 (01) : 1 - 8